Novavax, Inc. (NVAX) — Analyst outlook / Analyst consensus target is. Based on 23 analyst ratings, the consensus is bullish — 17 Buy, 3 Hold, 3 Sell.
The consensus price target is $14.50 (low: $11.00, high: $18.00), representing an upside of 72.8% from the current price $8.39.
Analysts estimate Earnings Per Share (EPS) of $-1.33 and revenue of $0.69B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.23 vs est $-1.33 (beat +7.2%). 2025: actual $2.72 vs est $2.23 (beat +21.7%). Analyst accuracy: 87%.
NVAX Stock — 12-Month Price Forecast
$14.50
▲ +72.82% Upside
Average Price Target
Based on 23 Wall Street analysts offering 12-month price targets for Novavax, Inc., the average price target is $14.50, with a high forecast of $18.00, and a low forecast of $11.00.
The average price target represents a +72.82% change from the last price of $8.39.
Highest Price Target
$18.00
Average Price Target
$14.50
Lowest Price Target
$11.00
NVAX Analyst Ratings
Buy
Based on 23 analysts giving stock ratings to Novavax, Inc. in the past 3 months
EPS Estimates — NVAX
87%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.23
vs Est –$1.33
▲ 7.7% off
2025
Actual $2.72
vs Est $2.23
▲ 17.9% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving.
Revenue Estimates — NVAX
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.682B
vs Est $0.685B
▼ 0.4% off
2025
Actual $1.123B
vs Est $1.064B
▲ 5.3% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
